[Skip to Content]
[Skip to Content Landing]
November 23, 1984

Polyneuropathy Following Vincristine Therapy in Two Patients With Charcot-Marie-Tooth Syndrome

Author Affiliations

From the Departments of Pediatrics (Drs Hogan-Dann, Fellmeth, and Kiley) and Neurology (Dr McGuire), David Grant USAF Medical Center, Travis AFB, Calif.

JAMA. 1984;252(20):2862-2863. doi:10.1001/jama.1984.03350200048021

The neurotoxicity of vincristine sulfate, a commonly used antineoplastic agent, has been well described. A literature review failed to reveal any absolute contraindications to the initial use of vincristine. We describe two patients with nodular sclerosing Hodgkin's disease in whom a rapidly progressive, but reversible, severe polyneuropathy developed when they were given a total of 4 mg of vincristine sulfate. Each was later shown to have the demyelinating form of Charcot-Marie-Tooth syndrome. This association suggests that the use of vincristine is contraindicated in patients with the demyelinating form of Charcot-Marie-Tooth syndrome.

(JAMA 1984;252:2862-2863)